Fmoc-AEEA-OH as a peptide spacer: what the 9-atom description means
Understand the defined AEEA linker, its reference identity data, and how to frame a spacer comparison without assuming a performance benefit.
Published by Talvenca
When a peptide design needs a spacer, “add some PEG” is not yet a complete material requirement. The team still needs to specify the structure, attachment points and number of units. Fmoc-AEEA-OH is one defined building block for that discussion.
A particular molecule, with two useful ends
The Novabiochem record for CAS 166108-71-0 describes Fmoc-8-amino-3,6-dioxaoctanoic acid as an amino-acid PEG spacer that can be incorporated by Fmoc SPPS. It has an Fmoc-protected amino end and a free carboxyl end.
| Reference field | Value |
|---|---|
| Name used in our catalogue | Fmoc-AEEA-OH |
| CAS | 166108-71-0 |
| Molecular formula | C21H23NO6 |
| Approximate molar mass | 385.4 g/mol |
| Supplier spacer description | 9 atoms |
These are structural reference data, not measured performance or a Talvenca batch specification.
The chain can be read as N–CH2–CH2–O–CH2–CH2–O–CH2–C(=O). Counting along that path gives nine atoms, including the amino nitrogen and carbonyl carbon. This is a structure-based explanation of the catalogue description: it does not mean nine ethylene-oxide repeat units or a fixed distance of nine nanometres.
Where a spacer question arises
One design question is whether a peptide and an attached group should be connected directly or through a defined spacer. Another is whether one spacer unit and a longer arrangement give different results. These are useful comparison designs when the planned coupling chemistry and protecting groups are compatible.
Write the proposed connection explicitly—for example, peptide–spacer–attached group—and mark the functional group at each junction. The schematic is a planning aid. It does not establish a validated route for an unspecified label, lipid or other partner.
If the practical concern is steric access, solubility or activity, decide which measurement will address it. A linker has changed the molecule; whether that change helps must come from the comparison. The word “PEG” alone does not supply a solubility value or a pharmacokinetic prediction for the resulting conjugate.
Keep a spacer comparison interpretable
An evaluation brief can record the following:
| Design decision | What to record |
|---|---|
| Attachment site | The specific atom or residue used |
| Spacer arrangement | Exact structure and number of units |
| Comparison | Direct attachment or another defined design |
| Outcome | The method and criterion used to judge the result |
Keep the common parts of the designs and the changed parts visible. Before interpreting the selected outcome, confirm which conjugate was actually obtained. A mass for the protected building block should not be copied into the expected-mass field for the final conjugate.
Move from the drawing to a material request
Use Fmoc-AEEA-OH when this exact identity matches the intended building block. If a project document says only “PEG linker,” resolve the structure first. Include the CAS, required amount and documentation requirements in a technical enquiry.
For a comparison study, label the quantities for each proposed material separately. The RFQ checklist provides a format for that first discussion.